Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report published on Monday,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.

A number of other analysts have also recently commented on IVVD. Morgan Stanley lowered their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a report on Tuesday, February 4th. Finally, EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Invivyd currently has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $1.24 on Monday. The firm has a 50 day moving average price of $0.80 and a 200 day moving average price of $0.87. The stock has a market cap of $148.33 million, a P/E ratio of -0.63 and a beta of 0.61. Invivyd has a 52-week low of $0.35 and a 52-week high of $4.74.

Insider Buying and Selling

In other Invivyd news, Director Terrance Mcguire sold 119,805 shares of Invivyd stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $0.42, for a total value of $50,318.10. Following the sale, the director now owns 3,568,274 shares of the company’s stock, valued at $1,498,675.08. This trade represents a 3.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 816,466 shares of company stock valued at $423,214. Company insiders own 17.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Mithril II GP LP acquired a new position in Invivyd during the fourth quarter worth $4,981,000. State Street Corp increased its stake in Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after buying an additional 35,904 shares during the last quarter. Deutsche Bank AG lifted its position in Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock worth $385,000 after buying an additional 227,463 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after buying an additional 204,188 shares during the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of Invivyd by 1,276.5% in the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after acquiring an additional 282,100 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.